NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GSK plc (NYSE: GSK). Shareholders who purchased shares of GSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT). Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Micron Technology, Inc. (NASDAQ: MU). Shareholders who purchased shares of MU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cardlytics, Inc. (NASDAQ: CDLX). Shareholders who purchased shares of CDLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of FTAI Aviation Ltd. (NASDAQ: FTAI).

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Crocs, Inc. (NASDAQ: CROX). Shareholders who purchased shares of CROX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ModivCare Inc. (NASDAQ: MODV). Shareholders who purchased shares of MODV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TELUS International (Cda) Inc. (NYSE: TIXT). Shareholders who purchased shares of TIXT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capri Holdings Limited (NYSE: CPRI). Shareholders who purchased shares of CPRI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Transocean Ltd. (NYSE: RIG).

Many Wall Street analysts think the S&P 500 will rise for the third consecutive year in 2025. Projections vary, but the consensus forecast appears to be that the index could jump in the ballpark of 10%.

Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia's declining revenues from patent expiration. Vafseo is now approved for dialysis patients and leverages AKBA's signature HIF pathway. So far, it has shown some early successes, which makes me optimistic. AKBA is also working on a Phase 3 trial for non‑dialysis CKD patients, which is scheduled for mid‑2025 to support a potential label expansion.

Delinquency rate growth is continuing to slow, creating a positive operating environment for SoFi. Refinancing demand exists, and SoFi is ready to capture the demand through its continued member growth and flywheel strategy. Despite about 100% stock price appreciation in recent months, I continue to believe that the company is reasonably valued.

Popular market analyst Tom Lee of Fundstrat recently called the financial sector his favorite investment for 2025.

Trump's 25% steel and aluminum tariffs rattle markets, fueling inflation fears and currency swings. Traders brace for volatility as the Fed weighs its next move.

SHANGRAO, China , Feb. 10, 2025 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that it ranked No.1 in the Global Solar Module Manufacturers Ranking 2025 report recently published by Wood Mackenzie, thanks to its outstanding technological capabilities and highly efficient module performance.